Global NewsHigh Priority (9/10)Uk

UK Drug Watchdog Recommends Novo Nordisk's Wegovy for Cardiovascular Risk Reduction

The UK's NICE has recommended Wegovy for obese or overweight adults to reduce heart attack and stroke risks, marking the first GLP-1 endorsement for cardiovascular use.

Key Points

  • NICE recommended Wegovy for cardiovascular risk reduction in obese/overweight adults
  • First GLP-1 drug endorsed for cardiovascular use in the UK
  • Eli Lilly pushing for NHS drug price increases and rebate scheme phase-out
  • Decision could expand NHS access to GLP-1 treatments for millions of patients

Full Details

On April 1, 2026, the UK's National Institute for Health and Care Excellence (NICE) recommended Novo Nordisk's Wegovy (semaglutide) for obese or overweight adults at risk of serious heart problems or strokes. This marks the first time a GLP-1 medication has been endorsed for cardiovascular risk reduction in the UK. The decision comes amid pressure from rival Eli Lilly, whose international businesses president Patrik Jonsson told the Financial Times that the company wants the NHS to regularly raise drug prices and phase out a multi-billion-pound rebate scheme if it hopes to resume investment in the UK market. The recommendation could significantly expand access to GLP-1 treatments for cardiovascular indications on the NHS, potentially benefiting millions of patients.

Why It Matters

This landmark recommendation could reshape cardiovascular disease treatment in the UK, potentially creating significant demand for GLP-1 therapies while intensifying pressure on NHS drug spending and pricing negotiations with pharmaceutical companies.

Sourcereuters.com

Get stories like this delivered daily

AI-curated news, personalized to your interests. Zero noise.

Start 7-Day Free Trial →

More in Global News